Compare International Business Machines Corp (IBM) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
International Business Machines Corp vs Moderna, Inc. — how do they compare? International Business Machines Corp trades at $227.13 (market cap $213.50B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: International Business Machines Corp is far larger — about 2.7× Moderna, Inc.'s market cap, and International Business Machines Corp pays a 2.98% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold International Business Machines Corp for 88 Days and Moderna, Inc. for 59 Days on average.
| IBM | MRNA | |
|---|---|---|
Market Cap | $213.50B | $78.65B |
Volume | 8,908,687 | 37,373,437 |
Sector | Technology | Health |
52-Week High | $329.23 | $203.46 |
52-Week Low | $205.77 | $22.36 |
Typical Hold Time | 88 Days | 59 Days |
Enterprise Value | $270.64B | $74.80B |
Dividend Yield | 2.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBM's stock trades at $226.61, up 2.77% today, with a bearish technical signal but strong fundamentals including a 15.52% net income margin and consistent earnings beats. Recent news highlights the launch of self-hosted deployment for its Bob AI platform, boosting AI consulting prospects. Revenue grew to $67.54B in 2025, though cash flow turned negative due to heavy investing.
Outlook is mixed: analyst consensus targets $255.50 with 47% buy ratings, but technical weakness and a high P/E of 20.13 suggest caution. Risks include cyclical demand swings and debt levels, while AI initiatives offer growth potential. Investors should weigh solid profitability against near-term volatility.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About International Business Machines Corp
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
